Asia Pacific Cancer Immunotherapy Market Research Report- Forecast till 2023

Market Scenario:

Cancer is a condition of uncontrolled cell growth. It is one of the deadliest diseases in the world and the second major cause for death. Cancer can be defined as an abnormal cell growth with the potential to spread to other parts of the body. There are over 100 types of cancer which have affected humans. According to a survey carried out by Pfizer, in 2012, 6.7 million cancer cases were registered in the Asia Pacific region which increased continuously. Additionally, according to the American Cancer Society, in 2015, 4.2 million newly diagnosed invasive cancer cases were registered in China. During the last decade, there has been a significant increase in the number of patients suffering from different types of cancer. Smoking is one of the most risk factors for the cause of cancer. Due to deteriorating lifestyle, smoking, and alcoholism, there is a rise in the incidence of cancer. Increasing cancer population is the major reason for increasing the Asia Pacific immunotherapy market. Different treatments are available in the market but the advantage of immunotherapy is its high effectiveness compared to other therapies. This therapy is effective for patients suffering from melanoma cancer where chemotherapy and other radiation therapy did not work. Increasing government support for research & development and increasing healthcare expenditure have fueled the market growth. However, side effects of the treatments and high cost of the therapy may slow the market growth during the forecasted period.

Asia Pacific immunotherapy market is expected to grow at a CAGR of 15.5% during the forecast period 2017-2023.

Intended Audience

- Government and private research companies
- Research and Development (R&D) Companies
- Drug Manufacturers and Suppliers
- Pharmaceutical Companies
- Medical Research Laboratories

Figure 1- Asia Pacific cancer immunotherapy market, by type of therapy
Segmentation

Asia Pacific cancer immunotherapy market is segmented on the basis of type of therapy, application and end users.

On the basis of type of therapy, the market is segmented into monoclonal antibodies, cancer vaccines, immunomodulators and other.

On the basis of application the market is segmented as lung cancer, blood cancer, melanoma, breast cancer and other.

On the basis of end user, the market is segmented into hospitals & clinics, research laboratories, cancer institute and others.

Regional Analysis

Asia Pacific cancer immunotherapy market is segmented into Japan, China, India, Australia, Republic of Korea and Rest of Asia Pacific. The major driving factor for the market is increasing number of patient population in India and China. China and India are the major contributor in the Asia Pacific cancer immunotherapy market. According to the NCIP, 0.33 million of the people in India are suffering from cancer and the number is continuously increasing owing to the changing lifestyle. Moreover, presence of huge patient population and increasing government support for research & development will fuel the growth of the market in India. China holds the second largest market for cancer immunotherapy market which is followed by Japan. Increasing government support, rapidly developing economy and increasing healthcare expenditure will boost the growth of China and Japan market. Moreover, availability of highly skilled healthcare professionals and rising acceptance of these therapies and increasing demand for the treatment have provided push for the growth of the market in these countries. Australia and Rest of Asia Pacific contribute the least share in the market.

Market Assessment
Key Players in the cancer immunotherapy market

The key players for the market are Amgen, Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), AstraZeneca Plc. (UK), GlaxoSmithKline Plc. (UK), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (US), Merck & Co., Inc. (US), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (US), Janssen Biotech, Inc. (US), Sanofi (France), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Oncomed Pharmaceuticals (US) and Immunomedics (US)
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis

Chapter 6. Asia Pacific Cancer Immunotherapy Market, by Type of Therapy
6.1 Introduction
6.2 Monoclonal Antibodies
Market Estimates & Forecast, 2017 – 2023
6.2 Cancer Vaccines
Market Estimates & Forecast, 2017 – 2023
6.3 Immunomodulators
Market Estimates & Forecast, 2017 – 2023
6.4 Other

Chapter 7. Asia Pacific Cancer Immunotherapy Market, by Application
7.1 Introduction
7.2 Lung Cancer
Market Estimates & Forecast, 2017 – 2023
7.2 Blood Cancer
Market Estimates & Forecast, 2017 – 2023
7.3 Melanoma
Market Estimates & Forecast, 2017 – 2023
7.4 Breast Cancer
Market Estimates & Forecast, 2017 – 2023
7.5 Other
Market Estimates & Forecast, 2017 – 2023

Chapter 8 Asia Pacific Cancer Immunotherapy Market, by End User
8.1 Introduction
8.2 Hospital
Market Estimates & Forecast, 2017 – 2023
8.2 Clinics
Market Estimates & Forecast, 2017 – 2023
8.3 Others
Market Estimates & Forecast, 2017 – 2023

Chapter 9. Asia Pacific Cancer Immunotherapy Market, by Region
9.1 Introduction
9.2 Japan
9.3 China
9.4 India
9.5 Australia
9.6 Republic of Korea
9.7 Rest of Asia Pacific

Chapter 10 Company Landscape

10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Merck & Co., Inc.
11.1.1 Overview
11.1.2 Product Overview
11.1.3 Financials
11.1.4 Key Developments

11.2 F. Hoffmann-La Roche Ltd
11.2.1 Overview
11.2.2 Product Overview
11.2.3 Financials
11.2.4 Key Developments

11.3 Novartis AG
11.3.1 Overview
11.3.2 Product Overview
11.3.3 Financials
11.3.4 Key Development

11.4 Amgen Inc.
11.4.1 Overview
11.4.2 Product Overview
11.4.3 Financials
11.4.4 Key Developments

11.5 Eli Lilly and Company
11.5.1 Overview
11.5.2 Product Overview
11.5.3 Financials
11.5.4 Key Developments

11.6 AstraZeneca Plc.
11.6.1 Overview
11.6.2 Product Overview
11.6.3 Financials
11.6.4 Key Developments

11.7 GlaxoSmithKline Plc.
Figure 11: F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 12: F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 13: Novartis AG: Key Financials
Figure 14: Novartis AG: Segmental Revenue
Figure 15: Novartis AG: Geographical Revenue
Figure 16: Amgen Inc.: Key Financials
Figure 17: Amgen Inc.: Segmental Revenue
Figure 18: Amgen Inc.: Geographical Revenue
Figure 19: AstraZeneca Plc: Key Financials
Figure 20: AstraZeneca Plc: Segmental Revenue
Figure 21: AstraZeneca Plc: Geographical Revenue
Figure 22: GlaxoSmithKline plc: Key Financials
Figure 23: GlaxoSmithKline plc: Segmental Revenue
Figure 24: GlaxoSmithKline plc: Geographical Revenue
Figure 25: Bayer AG: Key Financials
Figure 26: Bayer AG: Segmental Revenue
Figure 27: Bayer AG: Geographical Revenue